MapLight Therapeutics Inc (MPLT) Stock Analysis

Verdict: WATCH (do not buy)

Strong 40-month cash runway provides CNS trial buffer, but peak insider dumping and analyst downgrades highlight elevated execution risk.

Investment score: 40/100

Analysis as of 2026-09-17

7-factor investment score

Valuation: 30/100 (weight 20%)
Financial Health: 60/100 (weight 15%)
Technical Momentum: 20/100 (weight 15%)
Earnings Quality: 35/100 (weight 15%)
Insider Sentiment: 40/100 (weight 10%)
Analyst Consensus: 70/100 (weight 10%)
Risk-Adjusted Return: 35/100 (weight 15%)

MapLight Therapeutics Inc opportunities and risks

What speaks for MPLT

Substantial cash position of $467.29M ($10.61 per share) yields approximately 40 months of cash runway based on 2025 FCF burn of -$138.61M.

What speaks against MPLT

Widespread executive insider selling near the 52-week high of $40.43 undermines management confidence.

Peers and competitors

SGMT
CBIO
ALT
CTMX
STTK

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
MPLT	n/a	0.0x	n/a	0.0%	0.0%	-36.2%
SGMT	n/a	0.0x	n/a	0.0%	0.0%	-12.1%
CBIO	n/a	53.7x	n/a	100.0%	-1371.5%	-24.1%
ALT	n/a	20325.7x	n/a	-48306.5%	-296000.0%	-12.2%
CTMX	n/a	32.9x	n/a	98.6%	-435.2%	-13.7%
STTK	n/a	531.4x	n/a	-750.9%	-5256.8%	-7.8%
Peer median	n/a	53.7x	n/a	0.0%	-1371.5%	-12.2%

Frequently asked questions about MapLight Therapeutics Inc (MPLT)

Is MPLT stock a good investment?

The TradeMates model rates MapLight Therapeutics Inc as WATCH (do not buy) with an investment score of 40/100. Strong 40-month cash runway provides CNS trial buffer, but peak insider dumping and analyst downgrades highlight elevated execution risk. This is algorithmic model output, not personal investment advice.

Is MPLT stock a buy?

The TradeMates model verdict for MPLT is WATCH (do not buy) with an investment score of 40/100. Treat this as a model signal to review, not a personal buy recommendation.